Partnerships OrphanPacific (Japan supply and distribution)
Indications
activated PI3K-delta syndrome (APDS)(Approved)
Status note Approved in the US, UK, Japan, Australia and Israel; additional launches being prepared.
Per-asset detail extracted from the 20-F filed 2026-04-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.